Elsevier

Biochemical Pharmacology

Volume 37, Issue 17, 1 September 1988, Pages 3229-3236
Biochemical Pharmacology

EFfects of two methylxanthines, pentoxifylline and propentofylline, on arachidonic acid metabolism in platelets stimulated by thrombin

https://doi.org/10.1016/0006-2952(88)90632-6Get rights and content

Abstract

[3H]Pentoxifylline and [3H]propentofylline were taken up by human platelets in a dose-dependent manner probably involving a passive diffusion through the plasma membrane. In vitro, the two drugs were able to inhibit platelet activation induced by thrombin. Serotonin secretion was reduced from 57% to 38% and 28% in the presence of 1 mM pentoxifylline and 1 mM propentofylline, respectively. Platelet aggregation was inhibited in the same way. Modifications of [y14C]arachidonic acid metabolism in human platelets stimulated by thrombin were then measured in the presence of drugs. Preincubation of platelets with 1 mM pentoxifylline or propentofylline inhibited the production of [14C] arachidonic acid metabolites, without any accumulation of free arachidonic acid, suggesting an action at a step preceding its conversion. Phosphatidylinositol and phosphatidylcholine hydrolysis measured upon thrombin treatment as well as phosphatidic acid production were reduced or suppressed in the presence of the drugs. A dose-dependence study showed that phosphatidylcholine hydrolysis was totally inhibited at 5.10−4M propentofylline, while phosphatidic acid formation was reduced by only 40%. Propentofylline was in general more efficient than pentoxifylline in inhibiting events occurring upon thrombin stimulation. Our results suggest that the two methylxanthines inhibit both phospholipase A2 and phospholipase C, the former displaying a greater sensitivity to the two drugs.

References (41)

  • A Beretz et al.

    Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate

    Biochem Pharmacol

    (1986)
  • HJ Chap et al.

    Action of highly purified phospholipase in blood platelets. Evidence for an asymmetric distribution of phospho-lipids in the surface membrane

    Biochim Biophys Acta

    (1977)
  • E Pohanka et al.

    Effect of a single pentoxifylline administration on platelet sensitivity, plasma factor activity, plasma-6-oxo-PGF1 and thromboxane B2 in healthy volunteers

    Prostagl Leukotr Med

    (1986)
  • MB Billah et al.

    Rapid decrease of phosphatidylinositol-4,5-bisphosphate in thrombin in stimulated platelets

    J Biol Chem

    (1982)
  • F Lanza et al.

    Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization

    Thromb Res

    (1987)
  • MF Simon et al.

    Activation of phospholipase C in thrombin-stimulated platelet does not depend on cytoplasmic free calcium concentration

    FEBS Lett

    (1984)
  • MF Simon et al.

    Selective inhibition of human platelet phospholipase A2 by buffering cytoplasmic calcium with the fluorescent indicator Quin 2. Evidence for different calcium sensitivities of phospholipases A2 and C

    Biochim Biophys Acta

    (1986)
  • AM Ehrly

    The effect of pentoxifylline on the deformability of erythrocytes and on molecular oxygen pressure in patients with chronic arterial disease

    J Med

    (1979)
  • H Gastpar et al.

    Study on platelet aggregation in vivo. III. Effect of pentoxifylline

    J Med

    (1977)
  • R Müller

    Haemorheology and peripheral vascular diseases: a new therapeutic approach

    J Med

    (1981)
  • Cited by (27)

    • Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel

      2011, JACC: Cardiovascular Interventions
      Citation Excerpt :

      Pentoxifylline is a PDE inhibitor currently recommended for the treatment of relief of peripheral vascular disease symptoms (23). Ex vivo and in vitro investigations have also demonstrated the antiplatelet properties of this compound (12,25–30). However, at difference of the PDE inhibitor cilostazol, to date there are no studies that have assessed the impact of pentoxifylline on platelet function profiles in patients receiving DAPT.

    View all citing articles on Scopus
    View full text